JNPMEDI Signs Strategic Business Agreement with Alchera to Link AI Image Recognition Technology with Medical Data Platform

JNPMEDI
25 Oct 2021 · 5 minutes read

JNPMEDI and AI image recognition company Alchera announced on the 21st that they signed a strategic business agreement to develop and expand the market for Decentralized Clinical Trial (DCT) solutions that are rapidly growing in the COVID-19 phase.

MOU

JNPMEDI and AI image recognition company Alchera announced on the 21st that they signed a strategic business agreement to develop and expand the market for Decentralized Clinical Trial (DCT) solutions that are rapidly growing in the COVID-19 phase.

Through this agreement, the two companies agreed to develop a non-face-to-face clinical trial solution by linking Alchera's AI image recognition technology, "AIIR CT" and JNPMEDI's medical data platform "Maven CDMS."

It is expected that the quality and efficiency of the clinical trial will be greatly improved by developing the previous manual self-certification and drug use verification with 'AIIR-CT's image recognition technology and automatically inputting the data into 'Maven CDMS'. In addition, based on the expertise and business network in the medical and AI fields of the two companies, we plan to collaborate to expand clinical trial-related services, including vitality test.

Tags:
MOU
AI
Alchera

Your Partner for a Successful Journey

JNPMEDI has been putting effort on bringing disruption on healthcare industry via integrating digital technologies to clinical research & trial operations.